Prognostic Value of "CD200" in Hematological Malignancies. Hematological Malignancies Comprise a Group of Malignant Clonal Disorders Arising From the Hematopoietic Tissues , Including Leukemia , Multiple Myeloma , and They Have a High Morbidity and Mortality
Not yet recruiting
- Conditions
- Hematological Malignancies
- Interventions
- Diagnostic Test: Flowcytometry on bone marrow aspiration
- Registration Number
- NCT06258629
- Lead Sponsor
- Sohag University
- Brief Summary
Prognostic value of 'CD200' in hematological malignancies Hematological malignancies comprise a group of malignant clonal disorders arising from the hematopoietic tissues , including leukemia , multiple myeloma , and lymphoma , and they have a high morbidity and mortality
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- NOT_YET_RECRUITING
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
- Newly diagnosed cases of hematological malignancis.
Exclusion Criteria
- Known cases of hematological malignancies and on treatment.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description control group Flowcytometry on bone marrow aspiration Age and sex matched healthy control individuals Case group after 6 months Flowcytometry on bone marrow aspiration Available number of patients with newly diagnosed as hematological malignancy after 6 months of starting treatment. Case group Flowcytometry on bone marrow aspiration Available number of patients with newly diagnosed as hematological malignancy
- Primary Outcome Measures
Name Time Method Level of CD200 diagnostic marker assessed by flow cytometry one year Prognostic value of CD200 in hematological malignancies
- Secondary Outcome Measures
Name Time Method